Dynavax Technologies

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. Our clinical-stage product candidates include: Phase 3 HEPLISAV-B ™ Adult Hepatitis B Vaccine Phase 1/2 Cancer Immunotherapy Phase 2 Asthma Therapy - Partnered with AstraZeneca In Europe, Dynavax manufactures Hepatitis B surface antigen for HEPLISAV-B.

Type
Public
HQ
Berkeley, US
Size (employees)
251 (est)+8%
Dynavax Technologies is headquartered in Berkeley, US

Dynavax Technologies Office Locations

Dynavax Technologies has office in Berkeley
Berkeley, US

Dynavax Technologies Metrics

Dynavax Technologies Summary

Market capitalization

$265.8 m

Closing share price

$4.5
Dynavax Technologies's current market capitalization is $265.8 m.

Dynavax Technologies Market Value History

Dynavax Technologies Company Life

You may also be interested in